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Abstract
Background: A new-generation low-energy linear accelerator (UNIQUE) was introduced in the clinical arena during
2009 by Varian Medical Systems. The world’s first UNIQUE was installed at Oncology Institute of Southern
Switzerland and put into clinical operation in June 2010. The aim of the present contribution was to report
experience about its commissioning and first year results from clinical operation.
Methods: Commissioning data, beam characteristics and the modeling into the treatment planning system were
summarized. Imaging system of UNIQUE included a 2D-2D matching capability and tests were performed to
identify system repositioning capability. Finally, since the system is capable of delivering volumetric modulated arc
therapy with RapidArc, a summary of the tests performed for such modality to assess its performance in preclinical
settings and during clinical usage was included.
Results: Isocenter virtual diameter was measured as less than 0.2 mm. Observed accuracy of isocenter
determination and repositioning for 2D-2D matching procedures in image guidance was <1.2 mm. Concerning
reproducibility and stability over a period of 1 year, deviations from reference were found <0.3 ± 0.2% for linac
output, <0.1% for homogeneity, similarly to symmetry. Rotational accuracy of the entire gantry-portal imager
system showed a maximum deviation from nominal 0.0 of <1.2 mm. Pre treatment quality assurance of RapidArc
plans resulted with a Gamma Agreement Index (fraction of points passing the gamma criteria) of 97.0 ± 1.6% on
the first 182 arcs verified.
Conclusions: The results of the commissioning tests and of the first period of clinical operation, resulted meeting
specifications and having good margins respect to tolerances. UNIQUE was put into operation for all delivery
techniques; in particular, as shown by the pre-treatment quality assurance results, it enabled accurate and safe
delivery of RapidArc plans.
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Background
During 2009, a new single-energy linear accelerator for
radiotherapy was introduced in clinical operation by
Varian Medical System (Palo Alto, CA, USA). This new
linac, called UNIQUE™ (UNIQUE in the following),
w a sa ne v o l u t i o no ft h ep r e v i o u ss e r i e so fl o w - e n e r g y
linacs. It incorporated new treatment modalities like
Volumetric Modulated Arc Therapy according to the
RapidArc
® method as well as advances in imaging
modalities. UNIQUE also improved gantry mechanical
control to allow safe operation of the advanced delivery
modes. The world’s first installation of UNIQUE took
place at the Oncology Institute of Southern Switzerland
and the machine started clinical treatments in June
2010.
Purpose of the present report was to summarise com-
missioning data in terms of main mechanical features as
well as beam characteristics. Secondly, the results of the
RapidArc commissioning on UNIQUE were presented
as well as an overview of the technical aspects of the
first clinical treatments. Several protocols and
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dardised procedures for beam data commissioning as
well as publications on quality assurance procedures
(among these, AAPM [1] or ESTRO [2] codes of prac-
tice), on analysis of results from mono or multi institu-
tional investigations [3] and on accuracy and precision
levels required in radiation therapy in general [4]. The
present report, was based on recommendation from the
Swiss Society of Radiobiology and Medical Physics [5]
and were tailored to the specific commissioning needs
to characterise a delivery system into the Eclipse treat-
ment planning system adopted at author’s institute.
Methods
UNIQUE linac was designed to generate and deliver a
single photon beam of nominal energy of 6MV with a
maximum dose rate of 600 (or 400 MU/minute depend-
ing on the version), and was developed with a vertical
standing wave linac, without bending magnet and steer-
ing coils. RF power generation was realised by a conven-
tional magnetron. It was equipped with a Millennium
multileaf collimator (MLC) with either 120 leaves (with
0.5 cm resolution at isocentre in the inner 20 cm and
1.0 cm resolution in the outer 20 cm) or with 80 leaves
(1.0 cm resolution over the entire 40 cm of maximum
field size). The couch top was derived from high energy
linacs and adapted for image guidance and rotational
therapy (the so-called Exact-IGRT couch top). Mechani-
cal and Enhanced Dynamic Wedges were implemented
on this new delivery platform as in other conventional
Varian linacs. Mega Voltage Imaging was guaranteed by
the amorphous silicon electronic portal imager PortalVi-
sion aS1000 (with pixel size of 0.392 mm) or aS1000/2
(with half resolution) operated by the so-called Exac-
tArm, a robotic positioning arm using an active control
and position correction system that compensates for
gravitational and mechanical undue movements even
during rotation. Patient anti-collision safety was imple-
mented by means of a laser-based system (LaserGuard).
Optional Image-guided patient repositioning was facili-
tated through 2D-2D MV image matching (Portal Vision
Advanced Imaging (PVAI) application) and by automatic
remote treatment couch movement managed by the
image review application without the necessity to enter
the room for couch operation.
Operational limits for asymmetric jaws were -2 cm
overtravel for x jaws and -10 cm for y jaws; similarly, all
other mechanical were implemented identical to other
existing delivery Clinac platforms from Varian.
Concerning RapidArc implementation on UNIQUE,
gantry rotation was controlled in the first generation of
machines, by a slipping clutch system. The dose rate
control of the UNIQUE accelerator was uses a principle
schematically summarised as follows. The gun pulse
trigger is always in coincidence with the magnetron
pulse; the dose rate is varied by changing the magnetron
pulse repetition frequency (PRF). The PRF frequency
varies between 50 - 400 pulses/sec depending on the
dose rate (up to 600 MU/min).
Every 50 ms, the control system of UNIQUE, com-
pares, in dynamic treatments, the number of cumulative
MU (resolution of 0.01 MU) delivered versus prescribed
and takes it into account for calculation of the PRF for
the next dose rate servo cycle.
A.UNIQUE Commissioning, Anisotropic Analytical
Algorithm configuration and periodic quality assurance
measurements
To determine the radiation beam characteristics and to
commission the Anisotropic Analytical Algorithm [6,7]
used for patients dose calculation and to assess the sta-
bility of the machine performance over time, the follow-
ing tests were performed and reported here.
i) Isocentre determination. A conventional star film
shot procedure was performed with X-Omat V
Kodak films. The specification for the isocentre
sphere diameters are 2 mm. The test was repeated
for different gantry, collimator and couch angle
settings.
ii) Output factors. Output factors were measured for
squared and rectangular fields in water at 10 cm
depth and data were compared against performed
calculations. Field sizes ranged from 3 × 3 to 40 ×
40 cm
2. Machine calibration was performed at iso-
centre at 10 cm depth for a field size of 10 × 10
cm
2.
iii) Output stability as a function of dose rate (called
MU stability) and linearity between output and MU
(called MU linearity) were assessed from periodic
quality assurance measurements in the range respec-
tively from 100 to 600 MU/minute and from 5 to
300 MU. MU stability was expressed as the ratio of
dose measured at a given dose rate to the reference
at 300 MU/min delivery. MU linearity was expressed
as the ratio of dose measurement per MU (dose/
MU) at given MU to the reference 100 MU delivery.
iv) Depth doses and beam profiles in principal x and
y axes were measured for a variety of square fields
with the same range as at ii)..
v) Similarly to what performed for open fields, also
fields modified by Mechanical and Enhanced
Dynamic Wedges were investigated in terms of pro-
files, depth doses, output factors and wedge trans-
mission factors.
Commissioning beam data measurements were per-
formed in water with ion chambers: 0.125 cm
3
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Page 2 of 10(Semiflex, PTW) for profiles and depth doses and out-
put factors or 0.6 cm
3 (Farmer, Nuclear Enterprise) for
absolute dose calibration. Source to phantom distance
SSD was set to 90 cm for all measurements. Depth dose
curves (PDD) were normalised to dmax and profiles were
normalised at the beam’s central axis. A field size of 10
×1 0c m
2 was used to determine dmax. Results of peri-
odic quality assurance measurements of beam character-
istics, including beam energy check, were reported in
this summary, too. These were obtained by means of
the portal dosimetry method GLAaS [8] as implemented
in the commercial EPIQA software (Epidos s.r.o., Brati-
slava, Slovak Republic). For beam profiles analysis, field
symmetry was defined as the maximum ratio between
symmetric points within the flattened region (80% of the
field size): max(D(x)/D(-x)) and expressed in percentage.
Homogeneity was defined within the flattened region as
(Dmax-Dmin)/(Dmax+Dmin) and similarly expressed in per-
centage. Field size was defined at 50% beam profile
intensity. Tolerances were derived from Swiss regula-
tions on quality assurance on linear accelerators for
medical usage [5].
Beam data measured for machine commissioning,
were compared against calculation performed in the
Eclipse Treatment Planning System for the Anisotropic
Analytical Algorithm AAA version 10.0.25 with a grid
size of 2.5 mm. Details on the beam processing for
AAA can be found in Fogliata et al [6]. In summary, the
AAA configuration phase consisted in the optimisation
of parameters and calculation kernels against the mea-
sured beam data. The optimisation is performed using
objective functions including the gamma index of Low
[9]. As an output of the AAA beam configuration phase
in Eclipse, plots of the gamma index after optimisation
are provided by Eclipse and reported here for depth
doses, before and after dmax, and for profiles in the flat-
tened region, within the field edge and outside the field
edge.
For some of the parameters, a direct comparison
against either published [6,8], or institutional data for
the 6MV beam generated by the high energy Clinac iX
available at authors institute was provided to appraise
performance of the UNIQUE beam delivery system in
the absence of other published references.
B.Imager isocenter accuracy and 2D/2D match and couch
shift accuracy
The imager isocenter accuracy QA test evaluated
whether the digital graticule generated by the PVAI
application coincided with the treatment isocenter. The
so-called marker-block phantom (a cubic phantom with
one fiducial radiopaque marker at the center) was
aligned on the couch with the treatment isocenter using
the wall lasers. MV images at different gantry angles
were acquired and analyzed measuring the distance
between the center of the marker and the digital grati-
cule inside the PVAI application (step 1 of the test).
To test the accuracy of the 2D-2D match procedure, a
set of 2 orthogonal images was acquired after a manual
pre-defined shift in the 3 directions of the center of the
phantom: the 2D-2D match was performed to re-align
the phantom, checking the proposed shift respect the
expected values (step 2 of the test).
The remote couch shift was applied according to the
previous match, and new images were acquired to test
the couch shift accuracy (step 3 of the test). This proce-
dure was derived from methods published by Yoo et al
[10]. Weekly checks were executed at 90° and 180°,
monthly frequency included also 0° and 270° but were
not reported here.
C.Rotational Stability
To assess overall accuracy and relevance of the gantry sag
and imager position (ideally corrected by the arm active
control of the Portal Vision system) during rotation, in
view of RapidArc commissioning and quality control,
tests were performed by measuring the displacement of
the center of a narrow field (0.4 × 0.4 cm
2)f r o mi t s
expected nominal position at 0,0 cm coordinates (in the
imager coordinates system) during an entire arc executed
either clock or counter-clock-wise [11]. Measurements
were performed with the PortalVision. Comparison with
similar measurements on an high energy linear accelera-
tor (Clinac iX), implementin gt h es a m ea r ma c t i v ec o n -
trol system, were provided for reference.
D. RapidArc commissioning and medium term (1 year)
machine performances
RapidArc (details about the principles and the algorithms
can be found in Cozzi et al [12]) commissioning tests were
performed according to the procedures described in the
seminal work of Ling et al [13]. These tests were per-
formed on the UNIQUE to assess the accuracy of the
machine in generating uniform dose delivery with various
combinations of dose rate, gantry speed and leaf speed
variations during rotational delivery. Tolerance on the
acceptable deviation of each dose band generated with a
given combination of the above parameters from the base-
line (defined as average of all the dose bands) was set to
2%. Results were provided for repeated series of measure-
ments during the first year of UNIQUE operation. Com-
parison with corresponding measurements on a high
energy linac (Clinac iX) were provided for reference. Data
were measured by means of portal dose images [11] and
analysed by means of the automatic tool implemented in
the Epiqa software.
RapidArc delivery with the UNIQUE was also assessed
by investigating the machine dynamic status recorded
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records were saved in the format of dynalog files where
each actual dynamic parameter was stored in association
to the corresponding expected parameter from delivery
steering instructions. Data were recorded and analysed
for each MLC leaf position, for the accumulated dose
and for the gantry angle. Results were reported for a set
of 12 clinical cases from our library of RapidArc plans
delivered on the UNIQUE and, for comparison, on the
Clinac iX unit.
Quality RapidArc delivery was also assessed at dosi-
metric level. For reproducibility, the same clinical plan
was delivered with a biweekly periodicity while each
patient treated with RapidArc on the UNIQUE under-
went standard pre-treatment quality assurance measure-
ments. Numerical analysis was performed calculating
the 2D gamma of Low [9] maps from the comparison of
calculated and delivered dose distributions at dmax
according to the GLAaS method [11] and scoring the
Gamma Agreement Index GAI with Distance to Agree-
ment threshold set to 3 mm and Dose Difference
threshold set to 3%. Results from clinical patients
included also a limited number of cases treated with
fixed gantry IMRT, and data were compared with the
corresponding results from other Varian linear accelera-
tors available at authors institute.
Results and discussion
A. UNIQUE Commissioning, Anisotropic Analytical
Algorithm configuration and periodic quality assurance
measurements
i. Isocenter determination
Figure 1 represented the result of the isocenter radius
determination by means of one standard star shot test. In
all conditions of gantry couch and collimator settings the
diameter of the sphere resulted smaller than 0.1 cm while
the machine specifications required it to be <0.2 cm.
ii. Output factors
Figure 2 summarized the results of the output factor
agreement between doses calculated in the TPS and the
corresponding measurements for fixed monitor units
(100 MU) in reference conditions(i.e. SSD = 90.0 cm,
depth = 10.0 cm). The entire map falls within ±0.6%.
The mean value is 0.0 ± 0.1%.
iii. Routine beam output check, MU stability as a function
of dose rate and MU linearity
Figure 3 showed the results of the routine beam output
tests performed weekly over a period of 1 year. The first
graph summarized the percentage dose difference from
the baseline for the reference field at 100 MU. Toler-
ance was ±2% while results fall all within ±1% and typi-
cally within ±0.5%. In table 1, a summary of the
machine output periodic control is presented with the
observed range and tolerances. The data are representa-
tive of one year period of machine operations. For direct
comparison, the corresponding results for the 6MV
beam generated by the Clinac iX of the institute are pre-
sented, too. MU stability and linearity results were sum-
marized in the second and third graphs of Figure 3. MU
stability with dose rate was assessed and results were
within 0.5% of the reference for all dose rates; MU line-
arity resulted on average within ±2% below 10MU and
with negligible deviations for higher values.
iv. Depth Doses and beam profiles
Figure 4 showed depth dose curves and profiles in the X
direction for the fields 3 × 3, 10 × 10, 20 × 20 and 40 ×
40 cm
2. The graph reported the measured data and the
corresponding curves computed from the TPS after
AAA algorithm configuration. The beam quality resulted
Figure 1 Standard star-shot test.f o rr a d i a t i o ni s o c e n t e r
determination with film: measured radius for gantry radiation
isocenter sphere resulted <0.1 mm
Figure 2 Dose accuracy for open fields as function of field size.
(10 cm depth, SDD = 90 cm): percentage difference of calculated
respect to measured dose, for 100 MU.
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Page 4 of 10in J10/J20 = 1.740 and TPR20/10 = 0.667 (Clinac iX,
6MV, respectively 1.732 and 0.673). The histogram sum-
marized the results of the gamma analysis during AAA
processing for the five different regions described in the
methods. For comparison, corresponding mean gamma
values for a Clinac 6EX previously installed at the
authors institute were compatible with the current: 0.17,
0.09, 0.12, 0,20 and 0.17 respectively with similar negli-
gible fraction of points with gamma greater than 1.
Part of Table 1 summarized the results of periodic
quality assurance control for field size, profile homoge-
neity and symmetry in the X and Y directions, and
beam energy. The energy check is reported as the ratio
between dose measured at different depths in solid
water with respect to the corresponding value at dmax.
As can be seen, all the findings are within tolerance, the
observed range was quite limited and there was a full
compatibility of results with data from high energy linac.
v. Mechanical and Enhanced Dynamic wedges
Figure 5 showed examples of mechanical and Enhanced
Dynamic Wedge profiles for a 15 × 15 cm
2 field from
measurements (acquired for both wedge types in the water
phantom, with PTW LA48 linear array for the EDW case)
and AAA calculations after algorithm commissioning. The
dose difference maps showed, as a function of the x and y
field side, the maximum percentage difference between
measurement and calculation for fixed MU (100 MU). No
deviations greater than ±2% were observed for all field
sizes and wedges. Average deviations per mechanical
wedge were: W15 -0.1 ± 1.0%, W30 -0.1 ± 0.9%, W45 -0.1
± 0.9%, W60 -0.4 ± 0.8%. Enhanced Dynamic Wedge
resulted in a much smaller range of deviations with typical
ranges within ±0.6%. Average deviations were: EDW10
-0.1 ± 0.2%, EDW15 0.2 ± 0.2%, EDW20 0.1 ± 0.2%,
EDW25 -0.1 ± 0.2%, EDW30 0.2 ± 0.2%, EDW45 0.4 ±
0.2%, EDW60 0.2 ± 0.3%. In table 1, the deviation from
reference of Wedge Factors for 20 × 20 cm
2 EDW fields in
the two directions In and Out, as measured with the
GLAaS portal dosimetry for weekly quality assurance pro-
tocols, was reported averaged over all wedge angles and
resulted compatible with 0%.
B. Imager isocenter accuracy and 2D/2D match and couch
shift accuracy
Figure 6 showed the results of imager isocenter (step 1)
and couch shift (step 3) accuracy over a six-month period
on weekly basis for both UNIQUE and Clinac iX. The
images were acquired at 180° and 90°, i.e. the standard
positions used for 2D imaging in our institute induced by
the most common start position of the first arc for Rapi-
dArc treatment (i.e. 179° as internal rule). To notice that,
for the Clinac iX, the 2 images were acquired respectively
with MV and kV detectors to minimize gantry move-
ments. The average results were respectively for UNIQUE
and Clinac iX 1.0 ± 0.3 and 0.5 ± 0.3 mm at 90°, 1.2 ± 0.3
and 0.4 ± 0.3 mm at 180° for step 1, 0.8 ± 0.3 and 0.6 ±
0.4 mm at 90°, 0.7 ± 0.3 and 0.5 ± 0.4 mm at 180° for step
3, always lower than acceptability criteria set at 1.5 mm.
About the disagreement between the remote couch shift
obtained from 2D-2D match and the expected shift of 1
cm (step 2), was always less than 1 mm.
C. Rotational Stability
Figure 7 showed the results of the gantry rotational sta-
bility tests. A small field (0.4 × 0.4 cm
2) was acquired in
cine mode with the portal imager and the relative move-
ment in x and y directions of its center of mass was plot
MU stability
MU/min
MU linearity
MU
Weekly Dosimetry
week #
Figure 3 Stability results over one year period for UNIQUE and
Clinac iX. Error bars refer to one standard deviation. A) Output
(weekly check): percentage dose deviation from reference. At week
n.42, machine output was re-tuned for both machines according to
institutional protocols. B) MU stability (monthly check): ion chamber
reading ratio for a fixed number of MU (100) between delivery at a
fixed dose rate (100, 200, 300, 400, 500, 600 MU/min) and reference
reading at 300 MU/min. C) MU linearity (monthly check): ratio
between ion chamber reading at fixed number of MU (5, 10, 50,
100, 200, 300 MU) with respect to the same for reference of 100
MU. Measurements are relative to a fixed dose rate of 300 MU/min.
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Page 5 of 10Table 1 Summary of the results of the periodic radiation beam quality assurance measurements
Unique Clinac iX
Output (% difference from ref.)
Tolerance: <2%
-0.3 ± 0.2% [-0.8,+0.2] -0.1 ± 0.4% [-0.9,+1.0]
Energy: Tolerance:<2%
%diff. ratio @5.6 cm/dmax 0.0 ± 0.0 [-0.1,0.1] 0.1 ± 0.1 [-0.2,0.6]
%diff. ratio @7.6 cm/dmax -0.1 ± 0.1 [-0.3, 0.1] -0.1 ± 0.1 [-0.3, 0.4]
%diff. ratio @11 cm/dmax -0.1 ± 0.1 [-0.3, 0.1] -0.0 ± 0.2 [-0.3, 0.6]
EDW _WF (% difference from ref.)
Tolerance: <2%
0.0 ± 0.2 [-0.1,0.1] -0.0 ± 0.3 [-0.1,0.5]
X dir. Y dir. X dir. Y dir.
Field Size [cm] 10 × 10 cm2,d max
Tolerance: <2 mm
10.03 ± 0.05(ref.10.02)
[10.00, 10.14]
10.06 ± 0.06(ref.10.07)
[9.99, 10.13]
10.10 ± 0.03(ref.10.02)
[10.08, 10.11]
9.99 ± 0.02(ref.10.04)
[9.94, 10.05]
Field Size [cm] 20 × 20 cm2,d max
Tolerance: <3%
20.13 ± 0.01(ref.20.13)
[20.10, 20.14]
20.14 ± 0.02(ref.20.13)
[20.11, 20.18]
20.21 ± 0.01(ref.20.21)
[20.18, 20.24]
20.09 ± 0.02(ref.20.02)
[20.02, 20.10]
Flatness [%] 10 × 10 cm2,d max:
Tolerance: <3%
0.8 ± 0.04 (ref.0.7) [0.7,
0.9]
0.9 ± 0.04 (ref.0.9) [0.8,
0.9]
1.2 ± 0.09 (ref.1.1) [1.0,
1.5]
0.8 ± 0.05 (ref.0.9) [0.8,1.0]
Flatness [%] 20 × 20 cm2,d max:
Tolerance: <3%
1.5 ± 0.04 (ref.1.5) [1.4,
1.6]
2.0 ± 0.06 (ref.1.8) [1.9,
2.1]
1.1 ± 0.12 (ref.1.0) [0.9,
1.4]
1.6 ± 0.10ref.1.7) [1.4,1.8]
Symmetry [%] 10 × 10 cm2,d max:
Tolerance: <103%
100.6 ± 0.2 (ref.100.6)
[100.4, 100.9]
100.3 ± 0.2(ref.100.4)
[100.1, 100.7]
100.5 ± 0.2 (ref.100.3)
[100.3, 101.1]
100.5 ± 0.2 (ref.100.3)
[100.2, 101.1]
Symmetry [%]20 × 20 cm2,d max:
Tolerance: <103%
101.1 ± 0.1(ref.101.3)
[101.0, 101.2]
100.4 ± 0.2 (ref.100.3)
[100.2, 100.7]
100.6 ± 0.2 (ref.100.4)
[100.1, 101.1]
101.4 ± 0.3 (ref.101.7)
[100.5, 101.8]
Measurements were performed by means of the GLAaS method (except output, where a 0.6 cm
3 ion chamber was used) on the UNIQUE linac and, as
comparison, on the Clinac iX linac operational at authors institute. Results derived from weekly controls over a period of one year and included stability of: dose
output, beam quality, EDW wedge factor, field size, beam homogeneity and symmetry. Measurement settings are reported in the first column. Mean results were
shown together with their standard deviation and range (in square brackets) for UNIQUE and Clinac iX in the second and third columns. Reference baseline was
reported within normal brackets
Figure 4 Measured and calculated open fields. (10 cm depth, SDD = 90 cm); calculated data refer to AAA algorithm version 10.0.25. First row:
examples of profiles and DD curves; second row: gamma analysis [1%,1 mm] on all data after beam processing phase.
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of monthly tests over a period of 1 year. As it can be
seen, the total residual motion due to gantry sag and
portal imager displacement due to gravity not compen-
sated by the active arm control system is on average
<0.6 mm with a maximum deviation from the nominal
center <1.2 mm and absolute maximum excursion in
the y direction <1.8 mm.
D. RapidArc commissioning and medium term (1 year)
machine performances
Figure 8 reported the results of the monthly tests per-
formed according to the referenced study of Ling et al
[13]. Test 0.1 referred to fixed gantry deliveries, while
tests 2 and 3 referred to rotational deliveries, with differ-
ent combinations of gantry speed, dose rate and MLC
speed. Each test aimed to generate uniform dose deliv-
ery in bands as shown in the figure. Tolerance of 2% for
the maximum deviation in each band from the baseline
defined as the average over all bands was required and
on average achieved in all cases for UNIQUE, even in
the challenging first band of test 2, where gantry inertia
was shown to be sometimes critical also in previous
experience. The tests performed at commissioning and
periodically over 1 year, demonstrated that the rota-
tional control system of UNIQUE is accurate and pre-
cise for RapidArc delivery and allowed for immediate
clinical implementation of this technique. Delivery para-
meters were investigated for plans of 12 patients deliv-
ered on both UNIQUE and Clinac iX by means of
dynalog files analysis. Figure 9 summarizes for each of
these test cases the average deviation from planned/
Figure 5 Wedges results : profiles and dose accuracy as function of field size, respectively A) Hard Wedges and B) EDW. Dose accuracy is
defined as: percentage difference of calculated dose respect measured dose, with fixed MU, at 10 cm depth, SDD = 90 cm.
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Page 7 of 10expected positions of the gantry, of the MU and of the
MLC. In all cases both machines showed i) very small
inter patient variability and ii) very small absolute devia-
tions from theoretical reference. Interestingly, the gantry
deviation plot showed better results on UNIQUE than
on Clinac iX. This systematic effect was linked to differ-
ent tightening of the chain or clutch systems but did
not induced measurable dosimetric effects.
Quality assurance of RapidArc delivery included also i)
delivery of standardized clinical test cases for RapidArc and
step_1 step_3
Figure 6 Image guidance on UNIQUE. Verification of 2D-2D image matching with weekly quality assurance procedure: average results (and
standard deviation) over one year period. For comparison results for the same procedure on Clinac iX are presented although these latter refer
to images acquired with the MV and kV systems, for steps 1 and 3 of the protocol.
Figure 7 Comprehensive test of the stability of the imaging center. (including PV mechanical stability and gantry sag motion) from
monthly quality assurance procedures. Test was performed acquiring portal images in continuous (cine) mode with a full gantry rotation. The
graph reported an example of the actual distance of the center C of the small radiation field from the physical image center in the X and Y
directions as a function of the gantry angle; the histogram showed the average deviations observed over a test period of one year as well as
the maximum distance, the maximum deviation in X and in Y directions and also the maximum excursion of the deviations; error bars are
expressed as 1 standard deviation.
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Page 8 of 10Figure 8 Summary of the RapidArc commissioning tests. (according to Ling et al [13]) performed as monthly checks over a period of one
year. The plot showed the dose output difference between readings in each uniform band from the average values for: test 0.1 (a dynamic
IMRT field with a 0.5 cm slit at 4 different gantry positions); test 2 (seven different combinations of dose rate and gantry speed during a
RapidArc delivery) and test 3 (four different combinations of MLC speed and dose rate during a RapidArc delivery). Recommended tolerance was
±2% for all tests. Images for tests 2 and 3 are corrected for the beam profile, rationing the band and the open field acquisitions.
Figure 9 Summary of the Dynalog Files analysis. for 12 test cases from real clinical patients delivered on both UNIQUE and Clinac iX linacs.
Plot showed the average deviations from reference or expected values during arc delivery of: gantry angle, accumulated MU and RMS of MLC
positions.
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treatment verification of clinical plans for all patients as
described in the methods. Table 2 summarized the results
of these measurements. GAI for the constancy tests resulted
fully equivalent with reference historical data from other
machine available at institute, further showing reliability of
the UNIQUE. At the time of submission, 152 patients
(192plans, 348 arcs) were treated for RapidArc on UNIQUE
and for these cases, GAI resulted of 97.3 ± 1.6% with a
complete overlap with historical results from a larger group
of 606 patients (797 plans, 1186 arcs) treated on a period of
31 months with RapidArc on Clinac iX at the institute.
Conclusions
A new-generation of low-energy linear accelerator,
UNIQUE, was recently introduced in the clinical arena (at
the moment with the exclusion of USA, Canada and
Japan) by Varian Medical Systems. The results of the com-
missioning tests and of the first period of clinical operation
of this new delivery system were presented in this report
for beam characterisation and modelling into the treat-
ment planning system, periodic quality assurance tests and
RapidArc operations. In all areas, UNIQUE resulted meet-
ing specifications and having good margins respect to tol-
erances, and was put into operation for all delivery
techniques. In particular, as shown by the pre-treatment
quality assurance results, it enabled accurate delivery of
RapidArc plans and this ended in the interruption of clini-
cal application of IMRT at our institute having replaced
the entire fixed gantry IMRT programme with RapidArc
now enabled on all delivery systems of our institute.
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Table 2 Summary of the stability control and of the pre-treatment patients quality assurance results for RapidArc and
IMRT treatments
Unique Clinac iX
GAI [%] constancy on a pre-treatment QA case (1 year data with a periodicity of
2 weeks)
RapidArc case 98.5 ± 1.1 [96.7,
99.6]
99.0 ± 0.3 [98.3, 99.4]
IMRT case 99.4 ± 0.1 [99.2,
99.2]
99.0 ± 0.4 [98.2, 99.3]
Clinical pre-treatment RapidArc QA GAI [%] 97.3 ± 1.6 [92.4,
99.9]
97.4 ± 1.8 [91.5, 99.9]
Number of arcs
(plans)
348 (192) [12
months]
1186 (797) [31
months]
Beside UNIQUE summary, a comparison with similar results from the Clinac iX operational at the institute is shown. Data are expressed as Gamma Agreement
Index GAI with Distance to Agreement and Dose Difference thresholds set to 3 mm and 3%. Measurements and calculations were performed according to the
GLAaS method by means of portal dosimetry.
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